The Truth About Ozempic and Muscle Loss: New Research Changes Everything

What You Have Probably Heard

The narrative around Ozempic and muscle loss goes something like this: GLP-1 medications cause rapid weight loss, and up to 25–40% of that weight loss is lean mass, which means muscle. Therefore Ozempic destroys your muscle. Lift weights and eat protein to prevent it.

That advice — lift weights, eat protein — is correct and important. But the underlying assumption driving it may be significantly overstated. New research published in 2025 in the journal Cell Metabolism suggests that most of the lean mass lost on GLP-1 medications like Ozempic may not be skeletal muscle at all.

Understanding the distinction matters enormously for how you think about training and body composition on these medications.

What the New Research Actually Found

Researchers at the University of Utah studied the effects of semaglutide-induced weight loss in mice, specifically looking at where the lean mass losses were coming from. The results were surprising.

Yes, lean mass decreased — about 10% overall, consistent with what clinical trials in humans have shown. But when researchers looked at where that lean mass was coming from, skeletal muscle was largely preserved. The lean mass losses were predominantly coming from other tissues — most notably the liver, which shrank by nearly half during treatment.

This is a significant finding. Lean mass is not just muscle — it includes organ tissue, connective tissue, bone, and water. When clinical trials report that 25–39% of weight lost on Ozempic is lean mass, they are measuring total lean mass, not skeletal muscle specifically. The assumption that lean mass loss equals muscle loss may be substantially wrong.

The researchers were careful to note that their findings were in mice, not humans, and that more research is needed to confirm whether the same pattern holds in human tissue. But the implication is important: the widespread fear that Ozempic is aggressively destroying your skeletal muscle may be based on a misreading of what the lean mass data actually measures.

Is Organ Tissue Shrinkage a Good Thing or Bad Thing?

For the liver, shrinkage is generally positive. Non-alcoholic fatty liver disease (NAFLD) is extremely common in people with obesity, and liver enlargement is a significant health risk. Liver shrinkage during GLP-1 therapy is largely considered a healthy outcome — the liver is returning to a more normal size as excess fat is cleared from the organ.

For other organs, the picture is less clear. The long-term implications of organ size changes from GLP-1 medications in humans are not yet fully understood. This is an area where the science is genuinely still developing.

The key takeaway: Not all lean mass is created equal. Losing liver fat tissue is very different from losing quadriceps muscle. Conflating the two in the way that much popular coverage does may be significantly misleading people about the actual muscle risk of GLP-1 medications.

What This Means — and Does Not Mean — for Athletes

This research does not mean you should stop worrying about muscle preservation on Ozempic. It means you should understand the risk more accurately.

Skeletal muscle loss on GLP-1 medications is real but may be smaller than commonly stated. When you are in a significant caloric deficit — which GLP-1 medications reliably create — your body does break down some skeletal muscle for energy, particularly if you are sedentary and not eating enough protein.

For active people eating adequate protein, skeletal muscle loss may be minimal. If you are resistance training 2–4 times per week and hitting 0.7–1.0 grams of protein per pound of goal body weight, you are giving your body both the stimulus and the raw materials to preserve skeletal muscle. The lean mass you are losing in that scenario is much more likely to be organ and connective tissue than quadriceps or biceps.

The case for strength training remains strong — just for different reasons. Even if the muscle loss risk from Ozempic is smaller than commonly believed, the case for resistance training during GLP-1 therapy is not weakened. If GLP-1 medications are primarily burning fat and reducing organ tissue while largely sparing skeletal muscle in active people, then resistance training combined with GLP-1 therapy creates an unusually favorable environment for body recomposition — losing fat while building or maintaining muscle simultaneously.

The Practical Takeaway

For athletes and active people on GLP-1 medications, here is what the current state of the research suggests:

Resistance train consistently. Not because Ozempic is destroying your muscle, but because you want to build and maintain the best possible body composition during a period of significant weight loss.

Eat adequate protein. Hit 0.7–1.0 grams per pound of goal body weight. Use our Protein Calculator to get your specific target.

Do not panic about every pound of lean mass on the scale. Total lean mass includes organ tissue, water, connective tissue, and bone — not just skeletal muscle. A decrease in lean mass during GLP-1 therapy may be a sign that the medication is doing exactly what it is supposed to do.

Stay informed as the research develops. This is a fast-moving area of science and what we know now will continue to evolve.